Apnimed

Cambridge, MA · Founded 2017 · Privately Held (backing)

Developer of a pharmacologic therapy designed to target orally dosed medicines, the key underlying neurobiological mechanisms that lead to airway obstruction. Apnimed is based in Cambridge, MA and was founded in 2017. It was valued at $434 million at its later-stage round in Mar 2026, the last priced event on record. It has raised $434 million across 8 recorded rounds; the latest was a $25 million early-stage round in Mar 2026.

PMV mark · valuation
$434.0M
Oct 2026
Priced at
its later-stage round
Mar 2026
Total raised
$434.3M
Last round
Early Stage VC
Mar 2026

Who backs Apnimed?

7 investors
InvestorType
Alpha Wave GlobalGrowth equity
Morningside GroupVenture capital
Tao Capital PartnersVenture capital
Columbia Seligman—
NexPoint (Asset Management)—
Sectoral Asset Management—
Seligman Technology Group—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Apnimed investors

7 investors are on record for Apnimed, including Alpha Wave Global, Morningside Group, Tao Capital Partners and Columbia Seligman. The early-stage round in Mar 2026 drew 2 investors.

Free account
More of Apnimed with a free account
  • ·Watch Apnimed: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 7 firms already write checks for companies like Apnimed. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View